Schubert & Co’s Pacira BioSciences PCRX Stock Holding History

Schubert & Co’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9	Closed	-$368	–	1090
2023 Q1	$368	Buy	9 +3	+50%	+$119	﹤0.01%	1473
2022 Q4	$232	Sell	6 -4	-40%	-$195	﹤0.01%	1508
2022 Q3	$1K	Buy	10 +1	+11%	+$56	﹤0.01%	1204
2022 Q2	$1K	Buy	9 +5	+125%	+$328	﹤0.01%	1234
2022 Q1	$0	Sell	4 -1	-20%	-$67	﹤0.01%	1265
2021 Q4	$0	Buy	+5	New	+$276	﹤0.01%	1212

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Schubert & Co's PCRX Position: Q2 2023 in Review

Schubert & Co sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 9 shares — an estimated $368 sold.

Schubert & Co first reported a position in PCRX in Q4 2021 and held it in 6 quarters. The position peaked at $1K in Q3 2022. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

Schubert & Co reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 9 Pacira BioSciences shares in Q2 2023, an estimated $368.
Schubert & Co first reported a position in Pacira BioSciences in Q4 2021 and held it in 6 quarters.
Schubert & Co's Pacira BioSciences position peaked at $1K in Q3 2022.
258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.